拉米夫定联合抗乙肝胎盘转移因子对慢乙肝疗效及免疫功能影响的观察  

作　　者：黎琮毅[1] 涂燕云[2] 方健强[1] 邱琦[1] 

机构地区：[1]广西壮族自治区江滨医院消化内科,530021 [2]广西中医学院附属瑞康医院肝胆内科,530011

出　　处：《浙江临床医学》2009年第4期358-360,共3页Zhejiang Clinical Medical Journal

摘　　要：目的观察拉米夫定联合抗乙肝胎盘转移因子治疗慢性乙型病毒性肝炎的疗效及对免疫功能的影响。方法将60例慢乙肝患者随机分为治疗组和对照组，各30例，两组均予拉米夫定100mg每日早晨空腹顿服1年，治疗组加用抗乙肝胎盘转移因子4ml肌肉注射，疗程6个月。检测治疗前及治疗后3个月、6个月、1年后两组患者的ALT水平及HBeAg、HBVDNA、T淋巴细胞亚群。结果治疗3个月、6个月、1年后，治疗组的HBVDNA阴转率和ALT复常率均显著高于对照组（P〈0．05），外周血CD4亚群水平上调，CD4／CD8比值趋于正常，与对照组相比差异有统计学意义（P〈0．05）。治疗1年后，治疗组HBVYMDD变异的发生率低于对照组。结论拉米夫定和抗乙肝胎盘转移因子联合治疗慢性乙型肝炎疗效显著，提高了机体的免疫能力，且疗效持久。Objective To observe the effect of combined application of Lamivudine and anti - HBV placenta transfer factor in treating patients with chronic hepatitis B and its influence on immunity. Methods 60 patients were enrolled and randomized into two groups：The treated group （30 cases） and the control group （30 cases）. Both groups received Lamivudine lOOmg daily for 12 month and treat group combined with anti - HBV placenta transfer factor 4mg daily for 6 month. Both groups were received 3 month and 6 month and 12 month treatment. ALT, HBeAg, HBVDNA, T - cell subset were evaluated. Results After 3 month and 6 month and 12 month treatment ,the negative rate of serumHBVDNA and ALT normalization rate in treated group were than in control group（P 〈 0. 05）. CD4 T -cell leves increased and CD4/CD8 became normal in treated group, and there significant difference between treat and control groups（ P 〈 0. 05 ）. the differentiation rate of HBVYMDD in treated group were than in control group after 12 month. Conclusions Lamivudine and anti - HBV placenta transfer factor combination can significantly treat patients with chronic hepatitis B and enhance body immune level for a long time.

关 键 词：慢性乙型肝炎 T淋巴细胞亚群 拉米夫定 抗乙肝胎盘转移因子 

分 类 号：R512.62[医药卫生—内科学] R245[医药卫生—临床医学]